<DOC>
	<DOC>NCT02982395</DOC>
	<brief_summary>The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Histologically confirmed diagnosis of superficial transitional cell carnimoma of the bladder (Ta, T1) Recurrent superficial bladder cancer refractory to Bacillus CalmetteGuerin (BCG) No previous intravesical therapy for 6 weeks No history of prior radiation to the pelvis Peripheral neuropathy ≤ grade 1 Eastern Cooperative Oncology Group (ECOG) performance status 0 t0 2 Adequate hematopoietic and hepatic parameters Muscle invasive disease (T2T4) Any other malignancy diagnosed within 2 years of study entry (Except basal or squamous cell skin cancers or noninvasive cancer of the cervix) Participation in any other research protocol involving administration of an investigational agent within 3 months before study entry History of sensitivity reaction to docetaxel Prescribed immunosuppressive medications because of a confounding medical condition Female patients who were pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Nanoxel M</keyword>
	<keyword>Docetaxel PM</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>BCG</keyword>
	<keyword>BCG refractory</keyword>
	<keyword>Non muscle invasive bladder cancer</keyword>
	<keyword>intravesical</keyword>
	<keyword>superficial bladder cancer</keyword>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Transitional cell carcinoma</keyword>
</DOC>